An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: Antiparkinson effects of Sinemet and protective effects of methylphenidate

Behavioural Brain Research

Volumn 156, Issue 2, 2005, Pages 201-213

  Fleming, Sheila M ^a,c   Delville, Yvon ^a   Schallert, Timothy ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

6 Hydroxydopamine; Methylphenidate; Neuroprotection; Parkinson's disease; Sinemet

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE UPTAKE INHIBITOR; METHYLPHENIDATE; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ASSAY; FORELIMB; IMMUNOCYTOCHEMISTRY; MALE; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SOMATOSENSORY CORTEX;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CARBIDOPA; CELL COUNT; DIFFERENTIAL THRESHOLD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; MOVEMENT; NERVE DEGENERATION; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, LONG-EVANS; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 9644289489     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.05.024     Document Type: Article

References (91)

1. P. Barneoud, E. Descombris, N. Aubin, and D.N. Abrous Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system Eur. J. Neurosci. 12 1 2000 322 336
2. T.M. Barth, T.A. Jones, and T. Schallert Functional subdivisions of the rat somatic sensorimotor cortex Behav. Brain Res. 39 1 1990 73 95
3. H.W. Berendse, J. Booij, C.M. Francot, P.L. Bergmans, R. Hijman, and J.C. Stoof Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell Ann. Neurol. 50 2001 34 41
4. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J. Neurol. Sci. 20 4 1973 415 455
5. R. Betarbet, T.B. Sherer, G. Mackenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 12 2000 1301 1306
6. E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, and D. Guilloteau Relationship between appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaque model of Parkinson's disease J. Neurosci. 21 17 2001 6853 6861
7. E. Bezard, S. Dovero, B. Bioulac, and C.E. Gross Kinetics of nigral degeneration in a chronic model of MPTP-treated mice Neurosci. Lett. 234 1 1997 47 50
8. E. Bezard, C.E. Gross, M.C. Fournier, S. Dovero, B. Bloch, and M. Jaber Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter Exp. Neurol. 155 1999 268 273
9. J. Biederman, D. Quinn, M. Weiss, S. Markabi, M. Weidenman, and K. Edson Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder Paediatr. Drugs 5 12 2003 833 841
10. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc. Natl. Acad. Sci. U.S.A. 80 1983 4546 4550
11. R. Camicioli, S.J. Grossmann, P.S. Spencer, K. Hudnell, and W.K. Anger Discriminating mild parkinsonism: methods for epidemiological research Mov. Disord. 16 2001 33 40
12. L.S. Carman, F.H. Gage, and C.W. Shults Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior Brain Res. 553 2 1991 275 283
13. M.A. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3 2002 574 579
14. J.W. Chang, S.R. Wachtel, D. Young, and U.J. Kang Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions Neuroscience 88 2 1999 617 628
15. D.L. Choi-Lundberg, Q. Lin, T. Schallert, D. Crippens, B.L. Davidson, and Y-N. Chang Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor Exp. Neurol. 154 1998 261 275
16. A.D. Cohen, J.L. Tillerson, A.D. Smith, T. Schallert, and M.J. Zigmond Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF J. Neurochem. 85 2003 299 305
17. B. Conner, D.A. Kozlowski, T. Schallert, J.L. Tillerson, B.L. Davidson, and M.C. Bohn The differential effects of adenoviral vector mediated glial cell line-derived neurotrophic factor (GDNF) in the striatum vs substantia nigra of the aged parkinsonian rat Gene Ther. 6 1999 1936 1951
18. B. Conner, D.A. Kozlowski, J.R. Unnerstall, J.D. Elsworth, J.L. Tillerson, and T. Schallert Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration Exp. Neurol. 169 2001 83 95
19. I. Date, Y. Yoshimoto, T. Imaoka, Y. Miyoshi, Y. Gohda, and T. Furuta Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging Brain Res. 621 1 1993 150 154
20. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp. Neurol. 175 2 2002 303 317
21. R. Di Paola, and R.J. Uitti Early detection of Parkinson's disease K.J. Palmer Drug treatment issues in Parkinson's disease 2000 Adis International Ltd. Hong Kong 1 11
22. D.M. Donovan, L.L. Miner, M.P. Perry, R.S. Revay, L.G. Sharpe, and S. Przedborski Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression Brain Res. Mol. Brain Res. 73 1/2 1999 37 49
23. H. Ehringer, and O. Hornykiewicz Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin Wochenschr. 38 1960 1236 1239
24. S. Fahn Description of Parkinson's disease as a clinical syndrome Ann. N. Y. Acad. Sci. 991 2003 1 14
25. C. Flores, D. Rodaros, and J. Stewart Long-lasting induction of astrocytic basic fibroblast growth factor by repeated injections of amphetamine: blockade by concurrent treatment with glutamate antagonist J. Neurosci. 18 22 1998 9547 9555
26. C. Flores, A.-N. Samaha, and J. Stewart Requirement of endogenous basic fibroblast growth factor for sensitization to amphetamine J. Neurosci. 20 RC55 2000 1 5
27. C. Flores, and J. Stewart Changes in astrocytic basic fibroblast growth factor expression during and after prolonged exposure to escalating doses of amphetamine Neuroscience 98 2 2000 287 293
28. P.A. Garris, E.A. Budygin, Philips PEM, B.J. Venton, D.L. Robinson, and B.P. Bergstrom A role for presynaptic mechanisms in the actions of nomifensine and haloperidol Neuroscience 118 2003 819 829
29. Y. Glinka, M. Gassen, and M.B. Youdim Mechanism of 6-hydroxydopamine neurotoxicity J. Neural. Transm. Suppl. 50 1997 55 66
30. L. Greenhill, D.H. Beyer, J. Finkleson, D. Shaffer, J. Biederman, and C.K. Conners Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder J. Attention Disord. 6 Suppl 1 2002 S89 S100
31. Y. Hua, T. Schallert, R.F. Keep, J. Wu, J.T. Hoff, and G. Xi Behavioral tests after intracerebral hemorrhage in the rat Stroke 33 10 2002 2478 2484
32. Y. Ichitani, H. Okamura, Y. Matsumoto, I. Nagatsu, and Y. Ibata Degeneration of the nigra DA neurons after 6-hydroxydopamine injection into the rat striatum Brain Res. 549 2 1991 350 353
33. Y. Ichitani, H. Okamura, D. Nakahara, I. Nagatsu, and Y. Ibata Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal DA neuron system: evidence for cell death in the substantia nigra Exp. Neurol. 130 2 1994 269 278
34. M. Jabor, S. Jones, B. Giros, and M.G. Caron The dopamine transporter: a crucial component regulating dopamine transmission Mov. Disord. 12 1997 629 633
35. J. Jankovic Levodopa strengths and weaknesses Neurology 58 4 Suppl 1 2002 S19 S32
36. R.E. Johnson, T. Schallert, and J.B. Becker Akinesia postural abnormality after unilateral dopamine depletion Behav. Brain Res. 104 1/2 1999 189 196
37. J.A. King, R.A. Barkley, Y. Delville, and C.F. Ferris Early androgen treatment decreases cognitive functioning and catecholamine innervation of the frontal cortex in an animal model of ADHD Behav. Brain Res. 107 2000 35 43
38. D. Kirik, C. Rosenblad, and A. Bjorklund Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal DA system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152 2 1998 259 277
39. D. Kirik, B. Georgievska, C. Burger, C. Winkler, N. Muzyczka, and R.J. Mandel Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-DOPA using rAAV-mediated gene transfer Proc. Natl. Acad. Sci. U.S.A. 99 7 2002 4708 4713
40. J.A. Kleim, T.A. Jones, and T. Schallert Motor enrichment and the induction of plasticity before or after brain injury Neurochem. Res. 28 11 2003 1757 1769
41. D.A. Kozlowski, B. Conner, J.L. Tillerson, T. Schallert, and M.C. Bohn Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connnections Exp. Neurol. 166 2000 1 15
42. R. Kuczenski, and D.S. Segal Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine J. Neurosci. 22 16 2002 7264 7271
43. J.W. Langston MPTP neurotoxicity: an overview and characterization of phases of toxicity Life Sci. 36 3 1985 201 206
44. J.W. Langston, P. Ballard, J.W. Tetrad, and I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 4587 1983 979 980
45. C.S. Lee, H. Sauer, and A. Bjorklund Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat Neuroscience 72 3 1996 641 653
46. A.J. Lees When did Ray Kennedy's Parkinson's disease begin? Mov. Disord. 7 1992 110 116
47. M.D. Lindner, M.A. Plone, J.M. Francis, and D.F. Emerich Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet Brain Res. Bull. 39 6 1995 367 372
48. M.D. Lindner, S.R. Winn, E.E. Baetge, J.P. Hammang, F.T. Gentile, and E. Doherty Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms Exp. Neurol. 132 1 1996 62 76
49. M.D. Lindner, M.A. Plone, T.D. Mullins, S.R. Winn, S.E. Chandonait, and J.A. Stott Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats Exp. Neurol. 145 1 1997 130 140
50. Y. Lui, D. Peter, A. Roghan, S. Schuldiner, G.G. Prive, and D. Eisenberg A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70 1992 539 551
51. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 1 2002 120 132
52. P. Mazzoni, and B. Ford The freezing of time as a presenting symptom of Parkinson's disease N. Engl. J. Med. 341 1999 1317 1318
53. A.L. McCormack, M. Thiruchelvam, A.B. Manning-Bog, C. Thiffault, J.W. Langston, and D.A. Cory-Slechta Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat Neurobiol. Dis. 10 2 2002 119 127
54. G.W. Miller, J.D. Erickson, J.T. Perez, S.N. Penland, D.C. Mash, and D.B. Rye Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease Exp. Neurol. 156 1999 138 148
55. G.W. Miller, R.R. Gainetdinov, A.I. Levey, and M.G. Caron Dopamine transporter and neuronal injury Trends Pharmacol. Sci. 20 1999 424 429
56. E.B. Montgomery Jr., W.C. Koller, T.J. LaMantia, M.C. Newman, E. Swanson-Hyland, and AW Kaszniak Early detection of probable idiopathic Parkinson's disease: development of a diagnostic test battery Mov. Disord. 15 2000 467 473
57. J.A. Obeso, F. Grandas, J. Vaamonde, M.R. Luquin, J. Artieda, and G. Lera Motor complications associated with chronic levodopa therapy in Parkinson's disease Neurology 39 11 Suppl 2 1989 11 19
58. M. Olsson, G. Nikkhah, C. Bentlage, and A. Bjorklund Forelimb akinesia in the rat Parkinson model: differential effects of DA agonists and nigral transplants as assessed by a new stepping test J. Neurosci. 15 5 Pt 2 1995 3863 3875
59. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 1998 Academic Press Inc. San Diego, CA
60. C. Pifl, B. Giros, and M.G. Caron Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium J. Neurosci. 13 10 1993 4246 4253
61. P. Riederer, and S. Wuketich Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis J. Neural Transm. 38 3/4 1976 277 301
62. T.E. Robinson, and K.C. Berridge The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res. Rev. 1 1993 247 291
63. T.E. Robinson, and K.C. Berridge Incentive-sensitization addiction Addiction 96 1 2001 103 114
64. T.E. Robinson, and B. Kolb Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine J. Neurosci. 17 1997 8491 8497
65. T.E. Robinson, and B. Kolb Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine Eur. J. Neurosci. 11 1999 1589 1604
66. T.E. Robinson, G. Gorny, E. Mitton, and B. Kolb Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex Synapse 39 3 2001 257 266
67. T.E. Robinson, Z. Mocsary, D.M. Camp, and I.Q. Whishaw Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system J. Neurosci. 14 5 Pt 1 1994 2687 2696
68. V. Sandoval, E.L. Riddle, G.R. Hanson, and A.E. Fleckenstein Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors J. Neurosci. 22 2002 8705 8710
69. H. Sauer, and W.H. Oertel Progressive degeneration in nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 59 2 1994 401 415
70. T. Schallert Aging-dependent emergence of sensorimotor dysfunction in rats recovered from dopamine depletion sustained early in life Ann. N. Y. Acad. Sci. 515 1988 108 120
71. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacology 39 5 2000 777 787
72. T. Schallert, T.D. Hernandez, and T.M. Barth Recovery of function after brain damage: severe and chronic disruption by diazepam Brain Res. 379 1 1986 104 111
73. T. Schallert, J.L. Leasure, and B. Kolb Experience-associated structural events, subependymal proliferation activity, and functional recovery after injury to the central nervous system: a review J. Cereb. Blood Flow Metab. 20 2000 1513 1528
74. T. Schallert, D. Norton, and T.A. Jones A clinically relevant unilateral rat model of parkinsonian akinesia J. Neural Transplant Plast. 3 1992 332 333
75. T. Schallert, and J.L. Tillerson Intervention strategies for degeneration of DA neurons in parkinsonism: optimizing behavioral assessment of outcome D.F. Emerich R.L. Dean III P.R. Sandberg Central nervous system diseases 2000 Humana Press Totowa, NJ
76. T. Schallert, M. Upchurch, N. Lobaugh, S.B. Farrar, W.W. Spirduso, and P. Gilliam Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage Pharmacol. Biochem. Behav. 16 3 1982 455 462
77. T. Schallert, M. Upchurch, R.E. Wilcox, and D.M. Vaughn Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum Pharmacol. Biochem. Behav. 18 5 1983 753 759
78. T. Schallert, and R.E. Wilcox Neurotransmitter-selective brain lesions A.A. Boulton G.B. Baker Neuromethods (series 1: neurochemistry), general neurochemical techniques 1985 Humana Press Totowa, NJ 343 387
79. C.W. Shults, J. Ray, K. Tsuboi, and F.H. Gage Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine Brain Res. 883 2 2000 192 204
80. D.D. Song, and S.N. Haber Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting J. Neurosci. 20 13 2000 5102 5114
81. R.G. Staal, K.A. Hogan, C.L. Liang, D.C. German, and P.K. Sonsalla In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridium J. Pharmacol. Exp. Ther. 293 2 2000 329 335
82. E.M. Stricker, and M.J. Zigmond Effects on homeostasis of intraventricular injections of 6-hydroxydopamine in rats J. Comp. Physiol. Psychol. 86 6 1974 973 994
83. J.L. Tillerson, A.D. Cohen, J. Philhower, G.W. Miller, M.J. Zigmond, and T. Schallert Forced limb-use effects on behavioral and neurochemical effects of 6-hydroxydopamine J. Neurosci. 21 12 2001 4427 4435
84. J.L. Tillerson, A.D. Cohen, W.M. Caudle, M.J. Zigmond, T. Schallert, and G.W. Miller Forced nonuse in unilateral parkinsonian rats exacerbates injury J. Neurosci. 22 15 2002 6790 6799
85. U. Ungerstedt Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system Acta Physiol. Scand. Suppl. 367 1971 95 122
86. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 3 1970 485 493
87. N.D. Volkow, G.-J. Wang, J.S. Fowler, M. Fischman, R. Foltin, and N.N. Abumrad Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain Life Sci. 65 1 1999 7 12
88. N.D. Volkow, G.-J. Wang, J.S. Fowler, S.J. Gatley, J. Logan, and Y.-S. Ding DA transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate Am. J. Psychiatry 155 10 1998 1325 1331
89. E.C. Wolters, C. Francot, P. Bergmans, A. Winogrodzka, J. Booij, and H.W. Berendse Preclinical (premotor) Parkinson's disease J. Neurol. 247 Suppl 2 2000 II 103 II 109
90. J.C. Wommack, and Y. Delville Chronic social stress during puberty enhances tyrosine hydroxylase immunoreactivity within the limbic system in golden hamsters Brain Res. 933 2002 139 143
91. M.J. Zigmond, and E.M. Stricker Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion Experientia 36 4 1973 436 438